Dexcom G7 CGM & Tandem t:slim X2 Insulin Pump: the AID System for Improved Diabetes Management
The Dexcom G7 Continuous Glucose Monitoring (CGM) System now integrates with the Tandem t:slim X2 insulin pump with Control-IQ* technology. This pairing functions as an automated insulin delivery (AID) system that can help individuals living with diabetes experience improved self-management.
Dexcom G7 is the most accurate CGM system†,1 available in Canada, clinically proven to lower A1C and improve time in range (TIR).2 When linked via Bluetooth with the Tandem t:slim X2 insulin pump, the Control-IQ* technology uses data from Dexcom G7 to adjust insulin delivery and keep glucose within range. Together, they form a hybrid-closed loop system that automates insulin delivery. AID systems can help individuals more easily manage their glucose levels, preventing highs and lows—and are clinically proven to support better health outcomes.3
Benefits of Dexcom CGM-powered AID Systems2
The clinical outcomes of recent trials, notably the 7-year COMISAIR study, provide compelling reasons for using an AID system such as Dexcom G7 combined with the Tandem t:slim X2 insulin pump with Control-IQ technology.2 The COMISAIR study, the longest and most comprehensive real-world study to date, shows that this treatment strategy is the most effective for managing diabetes in adults living with T1D across all studied age groups, compared to all other treatment strategies.
The study revealed that the Dexcom CGM-powered AID system was superior to all other treatment options in reducing A1C and improving TIR. Specific results included:
- A1C average of 6.6% (target range: <7%)
- TIR average of 78.3% (target range: >70% 3.9-10mmol/L)
AID Systems Are a Recognized Standard of Care for T1D
Diabetes Canada, the American Diabetes Association and the International Society for Pediatric and Adolescent Diabetes consider automated insulin delivery systems as a standard of care for individuals living with T1D. The American Diabetes Association notes that clinical data confirms the benefits—including improved TIR and A1C—of AID systems for individuals with T1D.4
For more information about the benefits of the Tandem t:slim X2 insulin pump for individuals living with T1D, please visit tandemdiabetes.ca.
To learn more about Dexcom CGM, the most connected CGM brand in the world,‡,1 please visit our connected partners page.
MAT-6594 V1.0
*This product may not be right for you. Always read and follow the label. The t:slim X2 insulin pump with Control-IQ technology is indicated for users with type 1 diabetes, 6 years and older. WARNING: Control-IQ technology should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 25 kg. Safety info: tandemdiabetes.com/safetyinfo.
†When compared with CGM systems commercially available in Canada as of November 2024.
‡Not all connections are available in Canada. To learn more about insulin pump integrations and compatibility with Dexcom CGM Systems, visit dexcom.com/en-ca/partnerships/integrations-and-compatibility.
1 Dexcom, data on file, 2024.
2 Beck RW, et al. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72. Diabetes Technol Ther. 2023;25(5):329-42.
3 Brown SA, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019;381(18):1707-17.
4 American Diabetes Association Professional Practice Committee; 7. Diabetes Technology: Standards of Care in Diabetes—2024. Diabetes Care 1 January 2024; 47 (Supplement_1): S126–S144. https://doi.org/10.2337/dc24-S007